After decades of stubbornly slow progress in asthma drug development, recent results from a trial of GlaxoSmithKline's mepolizumab hint at a brighter future.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Holmes, D. Moving from an asthma pipe dream to a pipeline. Nat Rev Drug Discov 11, 737–738 (2012). https://doi.org/10.1038/nrd3858
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3858